Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment

Glycobiology

Volumn 24, Issue 12, 2014, Pages 1283-1290

  Croci, Diego O ^a   Cerliani, Juan P ^a   Pinto, Nicolas A ^a   GMorosi, Luciano ^a   Rabinovich, Gabriel A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiogenesis; Galectin 1; Galectins; Glycosylation; Hypoxia; Immunotherapy; Lectins; Vasculature

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR 2; GALECTIN; GALECTIN 1; GALECTIN 2; GALECTIN 4; GALECTIN 8; GLYCAN; GLYCOSYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; LECTIN RECEPTOR; MANNOSIDASE; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SCATTER FACTOR; SULFOTRANSFERASE; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; POLYSACCHARIDE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; HYPOXIA; KAPOSI SARCOMA; LUNG ADENOCARCINOMA; MELANOMA; MICROGLIA; NONHUMAN; PANCREAS ADENOCARCINOMA; PREECLAMPSIA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TH1 CELL; TH17 CELL; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR BIOLOGY; ANOXIA; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANOXIA; ENDOTHELIAL CELLS; GLYCOSYLATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; SIGNAL TRANSDUCTION;

EID: 84922977686     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu083     Document Type: Review

References (67)

1. Bastón JI, Barañao RI, Ricci AG, Bilotas MA, Olivares CN, Singla JJ, Gonzalez AM, Stupirski JC, Croci DO, Rabinovich GA, et al. 2014. Targeti ng galectin-1-induced angiogenesis mitigates the severity of endometriosis. J Pathol. doi: 10.1002/path.4397
2. Bax M, García-Vallejo JJ, Jang-Lee J, North SJ, Gilmartin TJ, Hernández G, Crocker PR, Leffle r H, Head SR, Haslam SM, et al. 2007. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol. 179:8216-8224.
3. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH. 2009. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 137:1124-1135.
4. Bergers G, Hanahan D. 2008. Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer. 8:592-603.
5. Boscher C, Dennis JW, Nabi IR. 2011. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol. 23:383-392.
6. Cardenas-Delgado VM, Nugnes LG, Colombo LL, Troncoso MF, Fernandez MM, Malchiodi EL, Malchiodi EL, Frahm I, Croci DO, Compagno D, et al. 2011. Modulation of endothelial cell migration a nd angiogenesis: A novel function for the tandem-repeat lectin galectin-8. FASEB J. 25:242-254.
7. Carlini MJ,Roitman P,Nuñez M,Pallotta MG,Boggio G,Smith D,Salatino M,Joffé ED,Rabinovich GA Puricelli LI. 2014. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients. Lung Cancer. 84 73-78.
8. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298-307.
9. Chen C, Duckworth CA, Fu B, Pritchard DM, Rhodes JM, Yu LG. 2014. Circulating galectins-2,-4 and-8 in cancer patients make important contributions to the increased circulation of sev eral cytokines and chemokines that promote angiogenesis and metastasis. Br J Cancer. 110:741-752.
10. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV . 2013. An IL-17-mediated paracrine network promotes tumor resistance to anti-Angiogenic therapy. Nat Med. 19:1114-1123.
11. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni DI, Dergan-Dylon LS, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 156:744-758.
12. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, et al. 2012. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-dri ven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med. 209:1985-2000.
13. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, Stupirski JC, Maz al D, Osinaga E, Toscano MA, et al. 2013. Targeting galectin-1 overcomes breast cancer-Associated immunosuppression and prevents metastatic disease. Cancer Res. 73:1107-1117.
14. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. 2005. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal pop ulation of pericyte progenitors. Cancer Cell. 8:211-226.
15. D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaestecker C, Baum L, Salmon I. 2013. VEGFR1 and VEGFR2 involvement in extra cellular galectin-1-And galectin-3-induced angiogenesis. PLoS ONE. 8:e67029.
16. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. 2007. Scheduling of radiation with angiogenesi s inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 13:3395-3402.
17. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232-239.
18. Etulain J, Negrotto S, Tribulatti MV, Croci DO, Carabelli J, Campetella O, Rabinovich GA, Schattner M. 2014. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors. PLoS ONE. 4: e96402.
19. Ferrara N, Hillan KJ, Gerber HP, NovotnyW. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 5:391-400.
20. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182-1186.
21. Freitag N, Tirado-González I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjaer SM, Schulz H, Wallukat G, Klapp BF, Nevers T, et al. 2013. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci USA. 110:11451-11456.
22. Garcia-Vallejo JJ, Van Dijk W, Van Het Hof B, Van Die I, Engelse MA, Van Hinsbergh VW, Gringhuis SI. 2006. Activation of human endothelial cells by tumor necrosis factor-Alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol. 206:203-210.
23. Garner OB, Baum LG. 2008. Galect in-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans. 6:1472-1477.
24. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, B ohlen P,Witte L . 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 8:841-849.
25. Heusschen R, Schulkens IA, van Beijnum J , Griffioen AW, Thijssen VL. 2014. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta. 18422:284-292.
26. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al. 2014. Bevacizumab plus Ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2:632-642.
27. Hsieh SH, Ying NW , Wu MH, Chiang WF, Hsu CL, Wong TY. 2008. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 26:3746-3753.
28. Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med. 358:2039-2049.
29. Ki MK, Jeoung MH, Choi JR, Rho SS, Kwon YG, Shim H, Chung J, Hong HJ, Song BD, Lee S. 2013. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene. 48:5449-5457.
30. Kitazume S, Imamaki R, Ogawa K, Komi Y, Futakawa S, Kojima S, Hashimoto Y, Marth JD, Paulson JC, Taniguchi N. 2010. ?2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling. J Bio l Chem. 285:6515-6521.
31. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, et al. 2013. A unique galectin signature in huma n prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 73:86-96.
32. Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M, Specht K, André S, Brinck U, Alken P, et al. 2007. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Histopathology. 51:681-690.
33. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ. 2005. Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 23:8932-894 1.
34. Loges S, Mazzone M, Hohensinner P, Carmeliet P. 2009. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15:167-170.
35. Machado CM, Andrad e LN, Teixeira VR, Costa FF, Melo CM, dos Santos SN, Nonogaki S, Liu FT, Bernardes ES, Camargo AA, et al. 2014. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGF?1-induced macrophages. Cancer Med . 3:201-214.
36. Mariñ o K, Bones J, Kattla JJ, Rudd PM. 2010. A systematic approach to protein glycosylation analysis: A path through the maze. Nat Chem Biol. 6:713-723.
37. Markowska AI, Jefferies KC, Panjwani N. 2011. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 286:29913-29921.
38. Ma rkowska AI, Liu FT, Panjwani N. 2010. Galectin-3 is an important mediator of VEGF-And bFGF-mediated angiogenic response. J Exp Med. 207:1981-1993.
39. Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, Munné-Collado J, Iglesias M, André S, Gabius HJ, Hwang RF, Poirier F, et al. 2014. Galectin-1 Drives pancreatic carcinogenesis through stroma remodeling and hedgehog signaling activation. Cancer Res . 74:3512-3524.
40. Mathieu V, de Lassalle EM, Toelen J, Mohr T, Bellahcene A, Van Goietsenoven G, Verschuere T, Bouzin C, Debyser Z, De Vleeschouwer S. 2012. Galectin-1 in melanoma biol ogy and related neo-Angiogenesis processes. J Invest Dermatol. 132:2245-2254.
41. Murdoch C, Muthana M, Coffelt SB, Lewis CE. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 8:618-631.
42. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156:899-909.
43. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A. 2010. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 127:2530-2541.
44. Ohtsubo K, Marth JD. 2006. Glycosylation in cellular mechanisms of health and disease. Cell. 126:855-856.
45. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220-231.
46. Piccolo E, Tinari N, Semera ro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F, Bagnato A, Lattanzio R, et al. 2013. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in huma n breast cancer cells and promotes angiogenesis. J Mol Med (Berl). 91:83-94.
47. Potente M, Gerhardt H, Carmeliet P. 2011. Basic and therapeutic aspects of angiogenesis. Cell. 146:873-887.
48. Rabinovich GA, Croci DO. 2012. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 36:322-335.
49. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumle e PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG. 2010. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 70:10090-10100.
50. Shojaei F,Wu X,Zhong C,Yu L,Liang XH,Yao J,Blanchard D,Bais C,Peale FV,kvan Bruggen N,et al 2007 Bv8 regulates myeloid-cell-dependent tumour angiogenesis Nature. 450 825-831.
51. Stanley P, Guidos C J. 2009. Regulation of Notch signaling during T-And B-cell development by O-fucose glycans. Immunol Rev. 230:201-215.
52. Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D, et al. 2012. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 37:249-263.
53. St. Croix BS , Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al. 2000. Genes expressed in human tumor endothelium. Science. 289:1197-1202.
54. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, et al. 2010. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70:6216-6224.
55. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J. 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 103:15975-15980.
56. Thijssen VL, Rabinovich GA, Griffioen AW. 2013. Vascular galectins: Regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 10:1359-6101.
57. Toscano MA, Bianco GA, I larregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, et al. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell d eath. Nat Immunol. 8:825-834.
58. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW. 2006. Gene expression of tumor angiogenesis dissected: Specific targe ting of colon cancer angiogenic vasculature. Blood. 108:2339-2348.
59. van Kooyk Y, Rabinovich GA. 2008. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 9:593-601.
60. van Wijk XM, Thijssen VL, Lawrence R, van den Broek SA, Dona M, Naidu N, Oosterhof A, van de Westerlo EM, Kusters LJ, Khaled Y, et al. 2013. Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis. ACS Chem Biol. 8:2331-2338.
61. Varki A, Kannagi R, Toole BP. 2009. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, Fr eeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. Chapter 44.
62. Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousse yn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, et al. 2014. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer. 134:873-884.
63. Willhauck-Fleckenstein M, Moehler TM, Merling A, Pusunc S, Goldschmidt H, Schwartz-Albiez R. 2010. Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling. Angiogenesis. 13:25-42.
64. Wu MH, Ying NW, Hong TM, Chiang WF, Lin YT, Chen YL. 2014. Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex. Angiogenesis. Advance Access published April 10 , 2014, DOI:10.1007/s 10456-014-9431-8.
65. Xu D, Fuster MM, Lawrence R, Esko JD. 2011. Heparan sulfate regulates VEGF165-And VEGF121-mediated vascular hyperpermeability. J Biol Chem. 286:737-745.
66. Zhao XY, Zhao KW, Jiang Y, Zhao M, Chen GQ. 2011. Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute mye loid leukemic cells. J Biol Chem. 286:36808-36819.
67. Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, et al. 2013. Ph armacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 72:879-887.